To further examine the functional requirement of RBM5, we utilized an alternative loss-of-function approach, RNA interference (RNAi), to target RBM5 mRNA in AML cells as a complementary approach to the DNA targeting strategy as CRISPR/Cas9. Here, RBM5 is linked to acute myeloid leukemia.